Because metformin has attracted interest as an antitumor agent in cancer prevention and treatment [39–53], we explored the possible impact of metformin treatment on metabolic rewiring induced by pathogenic mutation of a single BRCA1 allele. This evidence concerns the gene BRCA1 and cancer.